Joint-Stock Company (S.A.)
Medisensonic
Medisensonic Spółka Akcyjna
Joint-Stock Company (S.A.)
Medisensonic Spółka Akcyjna
Medisensonic Spółka Akcyjna (KRS 0001018765, NIP 1251672921) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. Medisensonic operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since February 9, 2023. Medisensonic's most recently reported net revenue was 405.9 K PLN for 2025.
Negative equity
Negative equity in 1 of 3 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Other activities
HTTPS://MEDISENSONIC.COM/Credibility rating
13.7 / 100
Very poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
38
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany w zarządzie. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
0
0/4 yrs
Board changes
3
3/4 yrs
PKD changes
0
0/4 yrs
Name changes
0
0/4 yrs
Data from 4 years of registry activity.
Payment reliability score from 2023–2025
Current: E (14/100)
Trend: deteriorating (-13.6 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Standard limit from 2023–2025
Current: 4.8 K PLN
Safe: 482.97 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Founded
February 9, 2023
3 years in operation
Legal form
Joint-Stock Company (S.A.)
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
695.0 K PLN
Shareholders
historical only
Board
2 people
Sup. board: 3 · Proxies: 1
Filed years
3 years
2023–2025 · profitable: 0/3
Registry entries
45
latest: July 30, 2026
Risk signals
Revenue
405.9 K PLN
2025
Net profit
-8.3 M PLN
2025
Assets
985.5 K PLN
2025
Equity
-2.9 M PLN
2025
EBITDA
-4.9 M PLN
2025
People holding roles at Medisensonic according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
Rate business credibility - Medisensonic.
No ratings
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
The beneficial owners of Medisensonic are: ROBERT GROMADA (PL).
No - all of Medisensonic's beneficial owners hold Polish citizenship.
Medisensonic's board has 2 members.
Latest reporting year
2025
Available years
4
Filing entries
0
Company Medisensonic has only one trademark, which is a trademark "SOREST".
3 most recent trademarks
SOREST
Filing date: 2022-09-07
activePublic-procurement proceedings in which Medisensonic appears as contractor or contracting authority - total contract value, signing dates, procedures and links to the official notices.
20 historical registry entries for Medisensonic
Change in Section 1 (basic data)
WR.VI NS-REJ.KRS/10369/26/865/ADE
Share capital change, Articles of association amended, Change in Section 1 (basic data)
WR.VI NS-REJ.KRS/18712/26/425
Board change, Commercial proxy change
WR.VI NS-REJ.KRS/21095/26/999
Filing documents submitted (4 documents)
Board change, Articles of association amended, Change in Section 1 (basic data)
WR.VI NS-REJ.KRS/25664/26/525
Competing companies or those operating in the same market segment as Medisensonic (industry: Research and development).
LUSINA· Research and development
Revenue 2021: 687.6 K PLN
WARSZAWA· Research and development
Revenue 2024: 536.4 K PLN
PODZAMCZE· Research and development
Revenue 2024: 466.1 K PLN
OŁAWA· Research and development
Revenue 2021: 426.4 K PLN
GDAŃSK· Research and development
Revenue 2023: 412.5 K PLN
GDYNIA· Research and development
Revenue 2024: 388.2 K PLN
